News

Seattle Genetics has posted a net loss of $34.86m for the third quarter 2010, or $0.34 loss per diluted share, compared to $19.83m, or $0.21 loss per diluted

Parexel has posted a net income of $17.79m for the first quarter 2010, or $0.3 per diluted share, compared to $12.44m, or $0.21 per diluted share, for the

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, provides integrated clinical, financial and connectivity solutions for ambulatory, inpatient and dental provider organizations. As per the

The trial, also referred to as Response, is a global, randomised study of efficacy and safety in polycythemia vera patients who are resistant or intolerant of hydroxyurea. Response

The grants are related to four of Palatin’s projects – melanocortin agonists for sexual dysfunction; melanocortin agonists for obesity and related metabolic syndrome; natriuretic peptide mimetic PL-3994 for

The increase in revenue was due to $44.2m of profit share earned from commercial sales of Enoxaparin sodium injection and the $5m regulatory milestone earned upon FDA marketing

Acorda has posted a net income of $12.44m for the third quarter 2010, or $0.31 per diluted share, compared to net loss of $19.43m, or $0.51 loss per

Coombs is appointed to the Audit and Corporate Governance Committees while Fischer is appointed to the Audit and Compensation Committees. Coombs, retired since 2008 from Tetra Technologies, served

In the CRL, the FDA has asked additional information in relation to the Linjeta (human insulin [rDNA origin]) injection 100IU/ml NDA for the treatment of type 1 and